ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 · 44.8% ORR at 6mg/kg dose in late-line CRC patients · ARR-217 was generally well-tolerated · ArriVent to host virtual webinar on Mo

Event · Clinical / regulatory
Product
ARR-217
Milestone
topline data
Indication
gastrointestinal malignancies

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 26, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AVBP
Bullish
high confidence
Mentioned
$AVBP
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AVBPBullishMed
01

Why it matters

The data provides a fresh catalyst for AVBP, likely prompting short‑term price appreciation and increased analyst coverage.

02

Market read

First‑report Phase 1 oncology data for a Nasdaq‑listed biotech, material for traders seeking early‑stage catalyst opportunities.

03

What to watch

Potential regulatory hurdles and competition from other ADC developers could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

The filing is an 8‑K Regulation FD disclosure announcing first‑in‑human results for ARR‑217 presented at ESMO 2026.

Company-level read

Ticker impact

$AVBPBullishHigh confidence
Context

ArriVent BioPharma disclosed initial Phase 1 data for its CDH17‑targeted ADC ARR‑217, showing a 44.8% ORR in pre‑treated colorectal cancer patients.

Expected impact

upward pressure as the market prices in the strong response rate and manageable safety profile

Evidence & confidence

Phase 1 data with double‑digit ORR and high disease control rates are material for a clinical‑stage biotech and often trigger short‑term buying.

Market effects

Positive data may boost sentiment toward ADC platforms and other CDH17‑targeting programs.

US and China investors may react, given the trial spans both regions.

Adds optimism to the broader oncology biotech space.

Counterpoint

Phase 1 data, while encouraging, remain early; efficacy must be confirmed in larger trials before substantial valuation uplift.

Key entities

  • ArriVent BioPharma, Inc.

    Clinical‑stage biotech developing ADCs.

  • Lepu Biopharma Co., Ltd.

    Collaboration partner providing exclusive rights outside Greater China.

Related articles

$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

$AVBPMed

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

$AVBPMedAI 8/10

Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

$AVBPMedAI 9/10

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.